RESP Biosensor Will Monitor Respiratory Issues at Home

Data may aid development of therapies for IPF and other lung disorders

Patricia Inácio, PhD avatar

by Patricia Inácio, PhD |

Share this article:

Share article via email
An illustration showing two people shaking hands.

Strados Labs is teaming up with Boehringer Ingelheim to conduct a pilot study leveraging its RESP Biosensor, a first-of-its-kind device designed to remotely monitor key changes in lung sounds, cough, and other respiratory issues in people with idiopathic pulmonary fibrosis (IPF) and other lung disorders.

In Boehringer Ingelheim’s study, the RESP Biosensor will be used to understand how well remotely monitoring cough and crackling sounds mirrors patients’ disease progression while they are at home. The end goal  is accelerating the development of new IPF therapies.

Built as a lightweight, noninvasive, wearable, and wireless device, the RESP Biosensor, which is approved by the U.S. Food and Drug Administration, facilitates prolonged wear and patient compliance. This means that higher quality data will be available to clinicians and care teams, allowing for earlier interventions and supporting the development of new IPF treatments.

Recommended Reading
An illustration of a mouse in a hand in a laboratory.

Scorpion Venom Cocktail Seen to Ease Lung Scarring in PF Mice

The RESP Biosensor has been used in clinical trials to monitor cough frequency and severity, along with wheezing and other abnormal sounds. It also has been used for remote monitoring in healthcare settings to tackle the issue of patient readmissions associated with chronic obstructive pulmonary disease (COPD), asthma, and other diseases.

Currently, lung function in IPF patients is assessed using spirometry, or breathing tests, which are performed in clinics, and require specialized equipment and personnel. One of the most commonly assessed parameters is forced vital capacity (FVC), which measures the total amount of air a person can exhale after a deep breath.

However, evidence suggests that cough may be associated with worse outcomes in patients with pulmonary fibrosis.

“Currently, disease progression in IPF is measured by a decline in forced vital capacity (FVC),” Nick Delmonico, CEO and co-founder of Strados Labs, said in a press release. “We are thrilled to help Boehringer Ingelheim explore cough and crackles as an additional method to monitor disease while allowing patients to stay in the comfort of their homes.”

The RESP Biosensor is part of Strados’ Cardiopulmonary Platform, a real-world and real-time monitoring platform for lung health. Harnessing the power of smart sensor technology, the platform collects and calculates key lung parameters, including the frequency of wheezing, coughing, and shortness of breath.

According to Strados, several studies have shown the superior effectiveness of continuous lung function monitoring with the RESP Biosensor when compared with electronic stethoscopes.

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums